Treatment of XXXX .

@entity1 @entity632 @entity137 @entity3003 @entity8779 @entity900 @entity6223 @entity786 @entity2879 @entity1778 @entity1891 @entity995
BACKGROUND: @entity995 is common in developing countries and little information about its treatment is available. The aim of this study is to report our experience in the treatment of these cases using a uniform approach. PROCEDURE: @entity1 with @entity995 including orbital extension, preauricular lymph node invasion and/or metastatic disease on diagnosis or after extraocular relapse admitted to the @entity6223 Garrahan from August 1987 to December 2000 were retrospectively reviewed. @entity1 were treated according to two different protocols (1987-1993 and 1994-2000). Treatment included: neoadjuvant combination chemotherapy followed by limited surgery in case of orbital extension (enucleation or resection of residual orbital mass) and adjuvant chemotherapy and radiotherapy. Chemotherapy included @entity786 , @entity1891 , @entity2879 , @entity632 (in protocol 87), @entity8779 (in protocol 94), @entity900 (in protocol 87), and @entity3003 (in protocol 94). RESULTS: Forty-one @entity1 were included. Fifteen of them had orbital or preauricular disease and had a 5-year event-free survival (pEFS) of 84%. Twenty-six had distant metastatic disease and non survived 5-years. One @entity1 died of @entity137 and one died in complete remission. One @entity1 had a secondary @entity1778 . The remaining adverse events included CNS and/or systemic relapse. CONCLUSIONS: This treatment strategy was highly efficacious for @entity1 with orbital and/or lymph node extension. Orbital exenteration is not necessary for these @entity1 . Those @entity1 with distant metastatic or CNS disease were not curable with this approach.
